Preserving the PromiseTM - We believe the promise of cell and gene therapies starts with the integrity of a single cell. Preserving the PromiseTM The human body can heal itself. Cell and gene therapies are designed to augment the patient’s ability to fight disease but only if the living cells behind those therapies remain viable and functional throughout the production processes. At BioLife Solutions, our mission is to protect the integrity of cells and provide trusted tools, services, and expertise that can enable our customers to advance the development and delivery of cell and gene therapies. We believe the future …

49 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

the control panel for the cell Nature is building tomorrow’s medicines. At Tolemy Bio, we are building the AI-native control panel for these cell-derived medicines, combining virtual cell models, big biological data, and wet-lab experimentation to help direct cellular systems toward better therapeutic outcomes. Our mission is to make cell biology more predictable, programmable, and scalable. Reach out to info@tolemy.bio learn more

Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology A.I.

Precision Transfections Trince is a spin-off company from Ghent University dedicated to advancing cell-based science and therapeutics by facilitating the delivery of molecules into cells, both in vitro and ex vivo. The company's LumiPore transfection platform, which is covered by a portfolio of pending patents, combines laser exposure with photothermal nanoparticles to convert light energy into heat to transiently permeabilize the cellular plasma membrane. It can be used to deliver a wide variety of effector molecules (e.g. nucleic acids or proteins) into virtually any cell type, including hard-to-transfect cells such as immune cells for cell therapies. The technology not only …

55 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Better Technology. Better Delivery. Developing a new generation of disease-modifying therapies. Driven by our proprietary Enhanced Delivery Oligonucleotide (EDO) platform, we are creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic neuromuscular and neurological disorders. Biotechnology, Chemistry, Biology, Bioscience, Life sciences, and Therapeutics

505 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

ElyssaMed® will develop the first therapeutic treatment for clinical use comprising several antigenic peptides (epitopes) derived from CTPP and selective for non-small-cell lung cancer, combined with an already marketed vaccine adjuvant. This product once administered to lung cancer patients, will amplify the patients' specific immune responses against tumor cells expressing the antigen CTPP and lead to their destruction.

Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Cellestia Biotech is pioneering innovative therapeutics based on novel modes of action to treat autoimmune diseases and multi-drug resistant cancers. Our clinical stage drug candidate, CB-103, has demonstrated both safety and biological activity in humans. Along with ongoing Phase 2 IITs for multi-drug resistant cancers, CB-103 is also poised to enter a Proof-of-Concept clinical study for graft-versus-host disease (GvHD) Biopharma, Oncology, Precision Medicine, Small Molecules, Targeted Therapy, Biotech, Cancer Therapy, Transcription Factors, Autoimmune Disorders, and Inflammatory Disorders

166 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering first-in-class, small-molecule therapies for immune-mediated and oncologic disorders We are a clinical-stage biotechnology company combining courage, conviction and cutting-edge science to develop breakthrough treatments for immune-mediated and oncologic disorders, with the hope of helping patients overcome their disease and live a better life. We are pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function and inhibit multiple drivers of disease via a single target. In modulating the function of profound intracellular regulators, our medicines have the potential for significant clinical impact in the most difficult-to-treat diseases. We believe the wide-ranging impact of our therapeutic platforms can be …

181 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Xeno-Free Human Platelet Lysate Experts for Cell Therapy & GMP Manufacturing | Home of the ELAREMTM Platform | Since 2015 PL BioScience GmbH's revolutionary ELAREMTM Human Platelet Lysate (HPL) platform represents a significant leap forward in regenerative medicine and advanced therapy. Built on proprietary extraction and optimization technology, ELAREMTM delivers xeno-free, naturally rich growth factors that power the expansion of stem cells, immune cells, and other therapeutically relevant cell types — outperforming Fetal Bovine Serum where it matters most: in consistency, ethics, and clinical readiness. From first-in-vitro studies through GMP-manufacturing of advanced therapy medicinal products (ATMPs), our platform enables seamless …

27 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Your Cell-Therapy Specialized CDMO Cell-Easy is a CDMO specialized in Cell Therapy. We support biotech, pharma, and public institutions with GMP development and manufacturing. Our mission: accelerate your Cell Therapy’s path to market, with patient access as our priority. ATMPs are not conventional biologics — they are living drugs. Our team brings hands-on expertise in cell culture across all cell types, engineered or not, addressing challenges in development, GMP manufacturing, and QC. Beyond core CDMO services — process diagnostics, development, GMP production, cell banking, cryostorage, and delivery — we also support sourcing of human biological materials and clinical trial setup, …

82 similar entities Type: Startup Activities: biotech healthtech manufacturing Technologies: Synthetic Biology

Theraonco enhance efficacity of wide range of payload agents and reduces their side effects Thanks to the specific assimilation of patented modified sugars equipped with chemical hooks by the tumoral cells, we can concentrate locally any type of payload through a reaction based on « click » chemistry (Nobel Prize, 2022) with carrier containing payload that “click” on the hooks. We want to use this approach to fight against cancer.

71 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Making tissue therapeutics possible to defeat serious disease Fluicell is transforming how we treat disease with one-of-a-kind tissue solutions for regenerative medicine and drug screening. With the groundbreaking Nexocyte platform, based on twenty years of disruptive and patent-protected R&D, we are creating new ways to target serious diseases using precision-engineered biological tissues. Our transplantable tissues have the potential to help patients living with uncurable tissue damage related to cardiac, pulmonary, metabolic, kidney and other diseases. Fluicell’s first ambitious goal is to develop transplantable tissues to cure type 1 diabetes, impacting the lives of millions of patients. Nexocyte-generated tissues also enable …

25 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Advancing precision oncology therapeutics designed to deploy multi-faceted inhibition to reverse cancer resistance AUM Biosciences is focused on advancing a clinical pipeline of precision oncology therapeutics designed to deploy multi-faceted inhibition strategies to reverse cancer resistance biotech, oncology, drug development, Asian-biotech, Precision medicine, Digitalhealth, cancer, and small molecules

626 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We build high tech equipment supporting end-to-end development and manufacture of cell and gene therapies. We build high tech equipment supporting end-to-end development and manufacture of cell and gene therapies. biotech, medtech, cell therapy, gene therapy, CAR-T, MSC, iPS, ATMP, Tissue Engineering, cell based therapies, biotherapies, RMAT, and Manufacturing

468 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Genewity is a biotech company developing autologous cell and gene therapies.

306 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Next-generation cancer treatment bringing the immune system one step ahead of cancer 🧬🟣 Brenus Pharma is a pioneering clinical stage biotech aiming to prevent cancer recurrence, the main challenge for solid tumors - causing 10M deaths each year worldwide. We developped a next-generation cancer treatment, thanks to our “off-the-shelf” therapeutic platform. Our lead candidate is a proteomic-driven immunotherapy targetting colorectal cancer (CRC), the 2nd deadliest cancer worldwide. - Our allogeneic platform generates therapeutics that efficiently educate the immune system, with more potent, diverse and novel targets than any existing therapies. (Characterized by advanced multiomics technologies) - We overcome limitations of …

171 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Apmonia Therapeutics SAS is a biotechnology company dedicated to developing anti-cancer immunotherapy strategies. Apmonia Therapeutics is a clinical-stage biotechnology company developing innovative peptide therapeutics designed to target the tumor microenvironment and improve outcomes for patients with solid tumors. Our approach focuses on overcoming one of oncology’s greatest challenges: the tumor microenvironment, a protective ecosystem that drives tumor growth, immune escape, and treatment resistance. Our lead candidate, TAX2, is a first-in-class peptide modulator of the TSP-1/CD47 pathway. Following strong preclinical results and CTA approval in Europe, TAX2 is entering Phase 1/2a clinical development in advanced solid tumors. immunologie and oncologie

40 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

StemTek Therapeutics is a start-up biotechnolgy company dedicated to accelerating drug discovery in cancer using cutting edge technology, world-class science and a stem cell centric point of view for cancer therapy. Our mission is to help design novel treatments for cancer targeting cancer stem cells.

124 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Making cell therapies more durable and effective through metabolic reprograming. At MPC Therapeutics, we are convinced that mitochondria, the small organelles at the core of the cell's metabolism, represent untapped therapeutic targets. Headquartered in Switzerland, our startup is focused on cellular rejuvenation to improve the performance of cell therapies and treat degenerative pathologies. Our novel approach uses proprietary first-in-class small molecules that specifically target mitochondria to trigger metabolic reprogramming. Visit our website for more info. Longevity, Mitochondria, Cellular rejuvenation, Immunotherapy, and CAR T cell therapy

32 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Beyond LNPs. Beyond the liver. A unique plant-based platform to unlock the potential of RNA therapies beyond vaccination Serendip Innovations is developing a next-generation RNA platform that integrates both RNA manufacturing and targeted delivery. Using a unique plant-based production system and phytovirus-like particles (phytoVLP), we generate functional long RNAs directly encapsulated into a proprietary non-viral vector designed for targeted extrahepatic delivery, repeat dosing, and scalable manufacturing. Our mission is to unlock the full therapeutic potential of RNA medicines beyond the limitations of conventional lipid nanoparticles (LNPs) and IVT RNA. One platform, one co-development partner. Biotechnology, Plant-based Bioproduction, Immunology, Oncology, Nanoparticulate …

57 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Smart control of the cell microenvironment - Bioengineered in vitro assays Experts in cell microenvironment control. At the forefront of the new challenges in biology, 4Dcell offers more reliable innovative study models, which are closer to the natural environment of the cell. 4Dcell technologies provide solutions for a myriad of applications. Among them, we highlight models for cancer, immune system, organs such as heart or gut, circulating cells, wound healing, neuronal network, stem cells and genetic disorders such as laminopathy. Years of research have led 4Dcell to develop an innovative 3D cell culture technology that enables the acquisition of more …

20 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

AI-Powered Cytometry & Cell Metabolism Profiling At Metafora, we develop innovative and impactful AI-powered cytometry & cell metabolism profiling solutions. We are passionate about cell biology. We leverage our unique cell metabolism and AI-powered data analysis platforms to turn disruptive single-cell technologies into impactful solutions that improve human health. biomarkeurs, cell metabolism, flow cytometry, data analysis, biotechnology, IVD tests, diagnostics, diagnostic tests, cell biology, neurometabolic diseases, metabolic diseases, oncology, multiple myeloma, and research

79 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Modulating T-regulatory cells to balance immunity Egle Therapeutics has been founded with a vision to become a game changer in the field of immunomodulating T-regulatory cells (Tregs) through the unique concept of Tregs’ starving while specifically targeting the most immunosuppressive ones.

210 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

coIMMUNE is a privately held, clinical stage immune-oncology company that will redefine cancer treatment using best-in-class cellular immunotherapies. Our allogeneic CAR-CIK technology platform for liquid and solid tumors is a novel CAR therapy that promises enhanced efficacy with greatly reduced toxicity.

106 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

The Cell Therapy Venture Builder MedXCell is a European cell therapy venture builder with a strong industrial mindset and a global perspective. Our focus is on technologies, techniques or novel applications in major diseases such as cancer, autoimmune, neurological and degenerative disorders. Established in 2018, we have offices in Switzerland, the EU (France) and the US (Cambridge, MA) and a multidisciplinary expert team with entrepreneurial, clinical, operational, business development and funding capabilities. Biotechnology, Cell Therapy, Immunotherapy, NK Cells, Mesenchymal Stromal Cells, Immuno-oncology, and Osteoarthritis

434 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Ready-to-use cell bank, for research, for patients Lymphobank - ready-to-use cell bank, for research, for patients. Lymphobank is a biotech company specializing in the supply of adult and placental blood cells for research use, the characteristics of which will be available online (www.lymphobank.fr), making it possible to choose the cellular product based on a donor of interest. Our services are focused on the development of cellular immunotherapy products. Furthermore, Lymphobank is developing an innovative allogeneic adoptive immunotherapy approach for hepatocellular carcinoma (the most common liver cancer and second cause of cancer death in the world, with nearly 750,000 deaths per …

55 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Building the Future of Precision Medicines through V-Body, RNA and In Vivo Cell Engineering Platforms. At Valerio Therapeutics, we are pioneering a new generation of precision therapies to tackle complex and underserved diseases. Our proprietary V-Body platform is based on two fully synthetic single-domain antibody (sdAb) libraries, derived from a human VH and a fully humanized VHH. Engineered for optimal performance, this ultra-small sdAb platform (~15 kDa) surpasses the limitations of current treatments by enabling deep tissue penetration and highly precise therapeutic delivery, ensuring superior efficacy and target engagement. Our approach integrates innovative target identification using advanced predictive models, antibody …

59 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Antineo aims to accompany customers in the preclinical development of novel anticancer agents. We provide services and strategic advice for preclinical development, optimal choice of in vitro and in vivo models as well as strategic input on potential indications to target in the therapeutic landscape. Développement préclinique, in vitro, ex vivo, in vivo, Preuve de concept, Expertise scientifique en pharmacologie, and Modèles à façon

143 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Playing music to cells Kolibri revolutionises the way we grow and engineer cells at scale using acoustic waves. 🔍 Book a discovery call: https://calendly.com/tamsin_kolibrilab/discovery-call Showing 10x increase in cell density and 50x reduction in production costs, our patented bioreactors help our partners in drug development unlock patient access to gene therapies, with a proof of principle in AAV gene therapy. Being cell-agnostic and scalable, our process has significant potential across a range of high-value cell-based therapies - or in the cellular agriculture space more broadly. gene therapy, biomanufacturing, cellculture, acoustics, hardtech, and biotech

139 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Building a sustainable sector and accelerate the discovery of new treatments tailored to each patient. French consortium to develop new experimental models of cancer in 9 cancer pathologies of interest (Lung, Pancreas, Breast, Liver, Ovary...) 3 major R&D axes: - Developing in vivo models and cell-based assays - Mimicking the human biology by humanizing the tumor microenvironment in mice - Studying the microbiota in cancer patients Oncology, Cancer research, Patient derived Xenograft, Cell lines, Ex vivo assays, Microbiota, Data mining , Translationnal medecine, Humanized mice, Biomarker, Research and Development, In vivo models, Ex vivo models, and Cancer

170 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

In-Cell-Art, is a biopharmaceutical company specializing in the preclinical and pharmaceutical development of solutions (DNA/RNA based vaccines or therapeutics) treating acquired or inherited diseases using patented bioinspired synthetic delivery systems (named Nanotaxi®) consisting of different chemical families (lipids, polymers). Its founder and research team, which includes a Nobel Laureate, have developed this unique intellectual property expertise and know-how based on 20 years of research in the field of supramolecular nucleic acids transfection agents. The vaccines and therapeutics developed by In-Cell-Art have been validated by numerous studies using infectious disease models (HIV, Flu, Dengue, dust mite, mycobacterium abscessus), therapeutic cancer models …

22 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Unlocking the Potential of Genetic Medicines with Anti-Silencing DNA Technology Houdini Bio has discovered a new layer of therapeutic DNA design, improving its potency inside cells, enabling enhanced durability, lower doses and improved cost effectiveness. Genetic medicines have the potential to transform how we treat disease. But as therapeutic DNA becomes larger, more synthetic, and more complex, cells increasingly recognise it as intrusive and silence its activity over time. Our AI-powered platform decodes and engineers escape routes around the cellular gene-silencing machinery, enabling sustained therapeutic expression whilst preserving biological function. By addressing the root biological mechanism which limits performance, we …

Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

"Designs the immunotherapy of tomorrow" At Allogenica, we are transforming cell therapies for a healthier tomorrow. Our mission is to disrupt the treatment landscape for cancer, rare diseases, and autoimmune disorders. We're developing a breakthrough cell therapy platform with the potential to: • Replace transplants: Providing less invasive, accessible alternatives for thousands of patients who currently have limited treatment options. • Expand access for all: With predictable safety and efficacy, we aim to make cell therapies available to a a broader patient population. • Dramatically reduce costs: By streamlining production, we aim to significantly lower the cost of cell therapies, …

37 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology

BIOMUNEX is a biopharmaceutical company focused on the discovery and development of breakthrough immunotherapeutics BIOMUNEX Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of breakthrough immunotherapies using its Unique BiXAb® technology to create next generation bi- and multi-specific antibodies. Our disruptive biological approaches target a number of cancer types, in particular where there are unmet medical needs. We are committed to provide oncologists and patients with immunotherapies that are novel, efficacious and prolong life expectancy.

28 similar entities Type: Startup Activities: deeptech biotech

Unlocking in vivo cell therapy with the next generation of gene editing technology Brink Therapeutics is developing next-generation recombinases — ultra-precise and efficient enzymes that surpass CRISPR-Cas9. We aim to revolutionize Cell and Gene therapies, enabling large-scale production to treat cancer, genetic disorders, and other diseases.

77 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Changing the game against solid tumors by overcoming the tumor microenvironment barrier The tumor microenvironment (TME) is a barrier that prevents conventional drugs from reaching the core of solid tumor. Persea is a biotech company developing a next-generation treatment that revolutionizes the fight against solid tumors by bypassing the tumor microenvironment barrier. Our drug candidate combines three therapeutic effects: targeting the tumor microenvironment, tumor destruction via a neighborhood (bystander) effect, and prevention of recurrence through activation of the immune response. Complete in vivo proof-of-concept results are available. Persea is one of the innovative projects selected and supported by the Paris …

Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Building the future of AI drug development with the data that matters. CAR-T is for more than just oncology. Using the full potential of gene editing, we are creating a therapeutic platform for cell based therapies that are not just disease modifying: they are curative and definitive. Cell-based Therapies and Machine Learning

97 similar entities Type: Startup Activities: biotech healthtech deeptech Technologies: Synthetic Biology SaaS A.I. Generative A.I.

KernalBio creates mRNA therapies that instruct specific cells on how to make their own medicine Kernal creates mRNA therapies to cure severe diseases including cancer. Our mRNA therapies instruct specific cells on how to make their own drugs. With roots at MIT, Harvard and Big Pharma, our team previously built a successful Biotech company and has deep expertise in mRNA space. synthetic biology, RNA design, immunotherapy, covid-19, cancer, and mRNA therapy

99 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Empower the body, cure the disease Mnemo Therapeutics is a Paris-based biotechnology company driven to create powerful immunotherapies by improving the body’s ability to detect and eradicate cancer. The paucity of actionable cancer-specific targets creates significant challenges in the field of immuno-oncology. To address this, Mnemo has developed a combination of in-silico and wet-lab pipelines to uncover new tumour-specific targets (called E-antigens) derived from the unexploited dark genome, and to develop multiple therapeutic modalities (i.e. cell therapy, TCE, ADC, vaccine) targeting these E-antigens. Mnemo is currently pursuing several discovery campaigns for E-antigens, with a plan to develop its proprietary tumour-specific …

8 similar entities Type: Startup Activities: biotech Technologies: Synthetic Biology

The Cell Coding Company bit.bio is an award-winning human synthetic biology company - our mission: coding cells for novel cures. We have developed an end-to-end platform for the creation of any human cell type. With our cutting-edge and patent-protected opti-ox precision cell programming technology, we can deterministically program human iPSCs into a chosen cell identity with unprecedented biological consistency at an industrial scale, and approximately 10 times faster than conventional methods. Our platform has the potential to unlock a new generation of medicines. Our io Cells research products provide scientists access to highly characterised, consistent, scalable human cells that enable …

55 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Re-arming the innate immune system against solid tumours LIFT BioSciences is pioneering a new class of immunotherapy for hard-to-treat cancers based on allogeneic Immuno-Modulatory Alpha Neutrophils (IMANs)®. Our proprietary, platform harnesses neutrophils’ innate tumour-homing and infiltrating attributes, combined with their ability to directly kill cancer cells and safely orchestrate broader immune responses, offering a powerful and antigen-independent treatment option to overcome cancer resistance mechanisms, like suppressive tumour environment and immune evasion. Backed by deep neutrophil biology expertise and a scalable manufacturing platform, LIFT is advancing a differentiated pipeline with application across multiple solid cancers. oncology, cell therapy, solid tumours, first-in-class, …

54 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We give access to the pulse of life Unlocking the Future of Cell Screening with Groundbreaking Innovation MicroOmix is a pioneering startup powered by patented technology from the CNRS and the University of Strasbourg, setting a new standard in high-throughput cell screening. Our cutting-edge platform analyzes cells based on the molecules they secrete, with a level of precision and resolution that is unrivaled. Secreted molecules are at the heart of critical biological processes—driving immune responses, cell migration, tissue regeneration, and differentiation. Emerging research reveals their pivotal role in disease progression and therapeutic effectiveness, but until now, accessing these insights has …

52 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Clinical-stage biopharmaceutical company developing transformative therapies to treat devastating human diseases Caribou Biosciences is a leading clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. Our next-generation genome-editing technology enables superior precision to develop cell therapies that are armored to potentially improve activity against diseases. We believe the future of cell therapy is off-the-shelf, and we are advancing our pipeline of off-the-shelf, or allogeneic, cell therapies from our CAR-T cell therapy platform as readily available treatments for patients with hematologic malignancies and autoimmune diseases. Next-generation CRISPR genome editing, allogeneic CAR-T cell therapies, oncology, and …

81 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Allogeneic Cell Therapy Platform that Leverages Natural Platelet Biology PlateletBio is an allogeneic cell therapy company focused on platelet biology. We are pioneers, discovering a new category in therapeutics. Our approach is one-of-a-kind, recreating nature’s legendary delivery cell. In doing so, we’re developing a cell therapy empowered to tackle previously unmet medical challenges. biotechnology, platelets, and drug discovery

131 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Unlocking the full potential of cell therapies for patients around the world SQZ Biotechnologies is a clinical-stage biotechnology company focused on unlocking the full potential of cell therapies to benefit patients with cancer, autoimmune and infectious diseases. The company’s proprietary Cell Squeeze® technology offers the unique ability to deliver multiple biological materials into many patient cell types to engineer what we believe can be a broad range of potential therapeutics. Our goal is to create well-tolerated cell therapies that can provide therapeutic benefit for patients and improve the patient experience over existing cell therapy approaches. With accelerated production timelines under …

74 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Redirecting Immune Memory from Pathogens or Childhood Vaccines to Target Cancer VerImmune is advancing Anti-tumor Immune Redirection (AIR): A Breakthrough Therapy that Redirects Pre-Existing Immune Memory from Childhood Vaccination or Infection to Fight Cancer

196 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Revolutionizing Cell Therapy with Protein Design Outpace is creating cell therapies with curative potential through protein design and cellular engineering. With an initial focus on solid tumors, Outpace is developing technologies that overcome the barriers to efficacy and safety by programming cells to make the right decisions inside patients. Outpace’s suite of technologies drive persistent activity of the cell therapy (OutLastTM), recruit a productive immune response in the tumor microenvironment (OutSmartTM), and achieve the potency (OutSpacersTM), specificity (Co-LOCKRTM), and safety (EGFRoptTM) necessary to unlock diverse cancer indications. Outpace’s internal and partnered pipeline approach is optimized for rapid clinical validation of …

Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

‘Off-the-Shelf’ Curative Cell Therapies About Us: Cell BioEngines is a US-based clinical-stage biotechnology company developing off-the-shelf allogeneic cell therapies by chemically reprogramming stem cell fate and function to treat serious and currently incurable diseases. Leveraging cord blood stem cells from highly compatible 'super-donors' and powered by its proprietary STEM-Space cellular reprogramming platform, the company delivers scalable cell products with reduced risk of immune rejection. Cell BioEngines’ competitive edge comes from a unique combination of a transgene-free scalable manufacturing platform enabled by advanced chemical reprogramming, rigorous HLA-guided design, and a population-informed biobank that supports broad patient coverage. Cell BioEngines lead clinical …

64 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Powering New Possibles in Cell Therapy Manufacturing Cell therapy has transformed cancer treatment, yet the hurdles of manufacturing patient-derived cell therapies remain a formidable challenge for the industry. Quality and scalability problems lead to high therapeutic costs and limit access to those life-saving treatments. By harnessing the power of cutting-edge semiconductor technologies, including silicon photonics seamlessly integrated into microfluidic cartridges, Sarcura is orchestrating a transformative shift. Central to Sarcura's mission is the creation of fully automated manufacturing systems endowed with real-time process and product control. This pioneering platform promises to usher in a new era of cost-effective and secure cell …

18 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Developing tomorrow's cancer therapies. Today. invIOs is a private biotech company focusing on discovery and development of novel cancer therapeutics that empower and educate the immune system to fight cancer. We leverage our deep expertise in immune-system activation to advance a focused pipeline of individualized and targeted approaches against solid tumors. Our focus is on earlier-stage development, with a sweet spot in bringing assets through discovery and pre-clinical development and into clinical trials. We launched in 2022 as a spin-out bundling the innovative oncology assets of APEIRON Biologics. Our highly motivated team of 35 people has deep expertise across the …

176 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Cure with genes Healthy cells for healthy people Somagenetix is a new company that aims at becoming a leading gene therapy company with first-in-class treatment for phagocyte-related disorders. We are spin-off from the University of Zurich and we are leveraging world-class scientific and clinical expertise to solve unmet medical needs through gene therapy. Carried by a highly experienced scientific team with over 17 years experience in gene therapy research, clinical development and applications, our mission is to cure all patients with Phagocyte Disorders. A cutting-edge technology with a complete & unique platform solving all challenges of ex-vivo gene therapies: specificity, …

45 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Changing the course of CNS disease Evox Therapeutics is harnessing and engineering the natural trafficking capabilities of extracellular vesicles to develop an entirely novel class of biotherapeutics. By combining groundbreaking exosome technology from well-renowned Oxford University and the Karolinska Institutet – the home of the Nobel Prize – we aim to revolutionise the treatment of a broad range of severe disease, with profound implications for human health. Based in Oxford, UK, Evox Therapeutics was founded in 2016 by Professor Matthew Wood of Oxford University, Assistant Professor Samir EL Andaloussi and Dr Per Lundin of the Karolinska Institutet, to capitalise on …

14 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

A cell-therapy technology company developing artificial membrane-binding proteins for oncology and regenerative medicine CytoSeek's mission is to use cell membrane augmentation technology to unlock the potential of next generation advanced therapies. Our novel cell membrane augmentation technology enables us to add new functionalities to various therapeutic cells. CytoSeek is engaged in proof of principle studies to demonstrate enhancement of cell therapies for cancer. We are looking to partner with cell therapy companies to bring these products to the clinic and ultimately enhance human health. Biochemistry, Immunology, Oncology, Regenerative Medicine, Cell therapies, and Proteins

75 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

LIVING CURES Prokarium is pioneering the field of microbial immunotherapy. Our pipeline is designed to unlock the next level of immuno-oncology by building on the most recent advances in cancer immunology. Prokarium’s lead program is focused on transforming the treatment paradigm in bladder cancer by orchestrating immune-driven, long-lasting antitumor effects. Biotechnology, Vaccines, Oral delivery, Immunology, Synthetic Biology, Oncology, Microbial Immunotherapy, and Immunotherapy

126 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

The CanVas platform is focused on developing novel cell therapies. The CanVas platform is spearheading the development of investigational allogeneic candidates for neurologic, rare and other serious diseases. Our world class team are dedicated to advancing a wave of investigational allogeneic products through excellence in translational research, clinical development and cell manufacturing. We are developing a pipeline of off-the-shelf cell therapies based on the pioneering Can-Vas platform. This could allow for the delivery of cell therapies to patients faster when they need it most and at greater scale. Our mission is to have a transformative impact on patients’ lives by …

60 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Going beyond treatment, striving for cures Cycuria Therapeutics is a preclinical-stage oncology startup based in Graz, Austria, founded by scientists from the Medical University of Graz, TU Munich and the University of Heidelberg. We are pioneering a novel protein-based targeted therapy for hematological cancers and beyond. Our approach selectively targets tumor and tumor stem cells while preserving healthy hematopoiesis and overall physiology. This enables durable efficacy without dose-limiting toxicity, as demonstrated in preclinical animal models and patient-derived disease models. By combining excellent tolerability with long-lasting efficacy, our novel therapeutic strategy aims to address significant unmet needs in cancer treatment, offering …

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

First-in-class ADCs tailored to attack advanced cancer Ona Therapeutics is pioneering the development of first-in-class antibody drug conjugates (ADCs) that exploit the molecular underpinnings of advanced cancer. We partner with renowned academics and clinicians to discover novel therapeutic targets from the unique biology of treatment refractory advanced cancer patients. Our approach combines privileged biology with Ona’s expertise in biologics. Together, we craft ADCs and antibody therapies, aiming to provide effective new treatments for patients with no remaining alternatives.

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Scancell is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. Scancell is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers. We have developed a pipeline of ‘off-the-shelf’ vaccines which induce immune responses and highly tumour specific monoclonal antibodies that redirect immune cells or drugs. Our advanced therapeutic vaccine programmes, SCOPE and ModiFY, have shown promising efficacy in Phase 2 trials, demonstrating long-term survival in metastatic melanoma and …

Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

Using mesenchymal stem cells to produce therapeutically meaningful extracellular vesicles. We are a recently incorporated limited company, spun out from the University of York from the Genever lab (www.geneverlab.info), which has over 20 years of experience in cell biology and regenerative medicine. We focus on musculoskeletal regeneration using mesenchymal stem cells (MSCs), with a view to translate our body of work into cutting edge therapeutics. Our current focal point is the field of extracellular vesicles (EVs), which have recently gained substantial traction as a next-generation therapeutic modality. We believe that current approaches have room for improvement in terms of consistency …

12 similar entities Type: Startup Activities: biotech healthtech Technologies: Synthetic Biology

Enabling manufacture of cell therapies at scale Cell therapy manufacturing was never designed to scale. Cellular Origins is changing that. We enable the manufacture of cell therapies at commercial scale through a flexible, factory-led approach. Our platform, Constellation, combines mobile robotics and AI to orchestrate the movement of patient material, equipment, and processes across the entire facility, while integrating with your leading bioprocessing technologies. By replacing fixed, linear systems with modular, parallelisable design, we enable intelligent capacity planning, built-in redundancy, and seamless scale-up without process redesign. The result is lower risk, greater efficiency, increased flexibility, and a faster path to …

59 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Changing the future of cancer care by accurately predicting patient response to therapies before treatment begins Kiyatec is disrupting cancer care by accurately predicting patient–specific response and non–response before treatment begins. We utilize the patient’s own living tumor cells to create functional 3D models to test a battery of cancer therapies in our CLIA-certified and research laboratories. Our goal is to enable physicians to isolate only the effective treatments for their patients as quickly as possible - making true personalized medicine a reality. Our approach has been validated through engagements with leading cancer hospitals, multiple top 10 pharmaceutical companies and …

120 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Kuur is committed to transforming the lives of patients with cancer and is leading the development of off-the-shelf engineered CAR-NKT cell therapies. Our approach combines the highly differentiated, natural biology of a specific subset of T cells, called natural killer T cells (NKT cells) and innovative chimeric antigen receptor (CAR) construct engineering. In combination, this delivers a very compelling and unique platform, that we believe has the potential to produce many future therapies targeting both hematological and solid tumors. Immunotherapy, Cancer, Oncology, T cells, TCR, CAR, CAR-NKT, clinical trial, NKT Cells, celltherapy, and lifesciences

69 similar entities Type: SMB Activities: biotech deeptech transporttech Technologies: Synthetic Biology

Cell therapy Acceleration and Innovation: Rethinking cell & gene therapy By Institut Curie CellAction (Cell therapy Acceleration and Innovation) is the cell and gene therapy platform of the Paris-Saclay Cancer Cluster (PSCC) at Institut Curie. A first in France, CellAction enables collaborative projects to be launched with industrial partners on a national and international scale. The aim is to accelerate the development of optimized cell and gene therapies. CellAction is founded on the centralization of key expertise required for the drug development process: - Institut Curie's highly qualified medical-scientific teams - Cutting-edge technologies for in vitro and in vivo testing …

70 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Bioceltix is changing the veterinary therapy standards. We develop innovative biopharmaceuticals based on stem cells. Bioceltix is a Wrocław-based and internationally oriented biotechnological company developing innovative, both stem cells and secretome based products, for companion animals. Our flagship technology for manufacturing biopharmaceuticals for veterinary use utilizes the therapeutic potential of allogeneic stem cells (one donor – many recipients). Owning a GMP production facility, we provide single technology for several species, diseases, and routes of administration. Our cutting-edge approach will allow the product to be batch-produced and ready for off-the-shelf sale. The veterinary medicines, based on the immunomodulatory mechanism of action …

58 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing first-in-class therapies designed to defeat chronic inflammation and fibrosis at the source. Our innovative therapeutic approach targets upstream amplifiers of disease offering potential treatments across a diverse array of therapeutic indications. Calluna Pharma is a clinical stage biotech company driven by a commitment to improve patient outcomes in diseases where existing treatments are sub-optimal. We believe in the power of immunology to push boundaries, challenge the status quo, and develop therapies that will make a real difference for people living with serious diseases.

43 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Hemispherian is a biotechnology company developing new treatments for the most aggressive types of cancer. Hemispherian is a biotechnology company developing new treatments for the most aggressive types of cancer. Our mission is to develop a new drug to treat Glioblastoma Multiforme. We aim to significantly increase life expectancy for patients, improve patient comfort, and generally increase the overall survival rates for GBM patients. cancer treatments, GBM treatments, and therapeutics

50 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Next generation cell therapies for ALK-positive cancer patients At ALKemist Bio we are developing TCR-T cells that possess the ability to specifically target ALK antigens found on ALK-positive cancer cells, primarily focusing on non-small cell lung cancer patients. By harnessing the power of the immune system and engineering T cells to precisely recognize and combat these cancerous cells, we aim to pave the way for more effective treatments aiming at improving the standard of care. biotech, immunooncology, oncology, alkpositive, celltherapy, TCR, and ALK

119 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

A lean biotech company aiming to develop revolutionary immune-based treatment for various cancers. Gritstone bio brings together a group of distinguished scientific founders and advisors, a highly experienced and diverse leadership team and a seasoned and successful board of directors to develop the next-generation of vaccines for cancer and infectious disease. With our unique approach to immuno-oncology and infectious diseases, we seek to generate a therapeutic immune response by leveraging insights into the immune system’s ability to recognize and destroy diseased cells by targeting select antigens. We started with a focus on tumor-specific neoantigens and more recently extended our programs …

34 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Enabling next generation medicines. A comprehensive platform and product suite for advanced therapeutics. Gene therapy, Synthetic Biology, Genome Engineering, and Functional Genomics

187 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Prolonging life and increasing life quality of cancer patients through innovative immunotherapies. Learn more. Elicera Therapeutics is a clinical stage cell and gene therapy company focusing on immunooncology. The company develops CAR T-cells against both solid and liquid tumors based on its proprietary technology platform, iTANK, for a parallell activation of an innate immune response against cancer. Elicera also develops next generation oncolytic viruses with three combined mode-of-actions, applicable for treatment of most cancers. Cell and gene therapy, immunooncology, CAR T-cells, Oncolytic viruses, and immunotherapy

55 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

A new class of cancer therapies using RNA-guided nucleases for specific cell depletion Akribion Therapeutics is developing a unique, RNA-guided, nuclease-based technology for programmable cell depletion. Its G-dase® E payload has the ability to kill cells by shredding DNA and RNA, but only if there is a highly specific match between the guide RNA and an intracellular RNA sequence, ensuring that only the targeted cells are affected, leaving healthy cells unharmed. Initially targeting HPV-induced Oropharyngeal Head & Neck Cancer (OPSCC), Akribion is exploring additional applications in oncology, autoimmune diseases, fibrosis, and infectious diseases. The flexibility and broad potential of Akribion's …

21 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

PrimeCell Therapeutics is a Czech biotechnological company focused on the field of regenerative medicine and modern therapy, whose goal is to develop and manufacture Advanced Therapies Medicinal Products that improve people's quality of life. The company PrimeCell Therapeutics was founded in 2007 with the aim of building globally competitive hi-tech centers in the Czech Republic, which will participate in the global process of development of modern cell therapy. PrimeCell Therapeutics enables doctors and patients with new treatment methods that use human cells and new materials, such as nanomaterials, to treat serious diseases. Thanks to its unique know-how in the field …

16 similar entities Type: Startup Activities: deeptech manufacturing Technologies: New Materials Synthetic Biology

A Path to SuperCellsTM Therapies GC Therapeutics Inc. (GCTx) uses synthetic biology to program patient-derived stem cells into any cell type with best-in-class efficiency (up to 10X), speed (up to 100X) and scalability. We dictate cells fates in a single step and have validated cells for many applications. We have also developed SuperCellsTM by tailoring cells for specific diseases. The core technology of GCTx was conceived, invented and perfected in Professor George Church’s lab at Harvard Medical School. We are a group of passionate biologists and tissue engineers whose goal is to bring this breakthrough approach to patients.

69 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Cell & Gene Therapy: Automated. Scalable. Accessible Limula provides an innovative solution for the production of the most personalised cancer treatments on demand and at scale. Our product is a unique proprietary platform can perform multiple steps of cell therapy manufacturing in a single device, using end-to-end automation and integrated process analytics. Bioproduction, Immunooncology, Cell therapy, Biotechnolgoy, Manufacturing, and CAR-T

132 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

A shift in cancer treatment methodology makes a world of difference. A shift in cancer treatment methodology makes a world of difference. Oniria Therapeutics is a spin-off from Vall d'Hebron Institute of Oncology (VHIO), the University of Barcelona (UB) and the Catalan Institution for Research and Advanced Studies (ICREA). Oniria Therapeutics is a biotech company focused on the development of first-in-class drugs in the field of precision oncology. It develops therapies to modulate and eliminate dormant tumor cells as a novel targeted strategy to overcome their persistence. Our flagship product allosterically activates TET2, a master epigenetic enzyme. Biotechnology, cancer, cell …

55 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Unravelling immune system function, one cell at a time Cellply is a life-science company focused on developing next-generation analytical tools enabling a deep characterization cancer immunotherapies, cell therapies and cell-based biotherapeutics. Our goal is to support the development of novel cancer immunotherapies by accelerating the R&D, advancing the quality control and monitoring the clinical response to these treatments. Through the use of proprietary microfluidic technologies, highly-automated analytical instruments and AI-powered image and data analytics, the Cellply platform defines the function of the immune system one cell at a time, combining functional data with other multiplex data and providing an unprecedented …

85 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. Synthetic Biology

Harnessing the Power of Tumor Gene Therapy to Turn the Tide in the Battle Against Cancer Headquartered in Cambridge, Massachusetts, Akamis Bio is a clinical-stage oncology company developing systemically administered immunotherapies to treat solid tumors, initially in patients with locally advanced rectal cancer (LARC). Its proprietary Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform is designed to deliver novel immunotherapeutic proteins, biomolecules and transgene combinations to treat solid tumors, with its lead clinical-stage program, NG-350A, driving intratumoral expression of a CD40 agonist monoclonal antibody. To learn more, please visit www.akamisbio.com Immuno-oncology and Re-programming the Tumor Microenvironment

82 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Precision Cancer Immunotherapy At Adularia, our technology is rooted in the discovery of a potent immune mechanism, which is based on insights from the symbiotic interplay between gut microbes and the immune system. We have identified a novel therapeutic target for immune oncology through the discovery of a mechanism by which bacterial metabolites activate a potent anti-tumor immune reaction through activation of tumor-residing macrophages. By leveraging insights from natural metabolic processes, we develop small molecule therapies that enhance the body’s native immune response against cancer. Biotech, Therapeutics, and Immuno-oncology

78 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Advancing Cancer Treatment Breakthroughs Carcinotech provides comprehensive solid tumor research services to advance drug development and enhance personalized therapy decisions. At the heart of its offerings is the proprietary Carcino3DTM bioprinting technology, which creates assay-ready, 3D tumors derived from patient biopsies. This innovative, translational approach delivers a predictive in vitro model, generating critical insights into therapeutic efficacy, and treatment optimization. Cancer research, 3D bioprinting , Cancer microenvironment, drug testing, oncology, assay services, oncology pre-clinical services, solid tumours, solid tumors, tumour microenvironment, tumor microenvironment, early phase drug development, and early drug discovery

186 similar entities Type: Startup Activities: manufacturing biotech deeptech Technologies: Synthetic Biology